611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Women May Be More Willing Than Men to Donate OrgansDNA Sensor Can Spot When COVID Is ContagiousTrials Show COVID Vaccines Well Worth It for Cancer PatientsCDC Endorses Booster Shots for Millions of AmericansChildhood Trauma Linked With Higher Odds for Adult Neurological IllsStudy Probes Relationship Between Migraines and SleepCancer in Hispanics: Good News and BadFDA Approves Pfizer Booster Shots for Seniors, High-Risk AmericansU.S. to Buy 500 Million More COVID Vaccine Doses for Global DonationAntibodies to Early Strains of COVID May Not Fight New Variants: StudyPregnant Women Who Get COVID Vaccine Pass Antibodies to NewbornsCDC Expert Panel to Weigh In on Vaccine BoostersWhich Kids Are at Highest Risk From COVID?4 Out of 10 Adults With No Known Heart Disease Have Fatty Hearts: StudyBooster Dose of J&J COVID Vaccine Increases ImmunityPost-Stroke Rehab: There's a Sweet Spot in the TimingCommon Form of Liver Cancer on the Rise in Rural AmericaCOVID Has Killed More Americans Than the Spanish Flu Did in 1918Telemedicine Gets High Marks for Follow-Ups After SurgeryPandemic Tied to Declining Birth Rates for U.S., Much of EuropeStudy Spots People at High Risk of Severe Breakthrough COVIDReview of Booster Shots for Moderna, J&J Vaccines Just Weeks Away: FauciDelta Variant Now Fueling 99% of U.S. COVID CasesLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company SaysFDA Panel OKs Pfizer Booster Shot for  People 65 or Older, But Not YoungerLong-Haul COVID in Kids Typically Ends Within 3 Months: StudyPfizer, Moderna Vaccines Still Offer Good Protection Against Severe COVID: StudyTrial Into Antioxidant for Parkinson's Disease Yields Disappointing ResultsIs Flu Ready for a Comeback? Get Your ShotCommon Eye Conditions Tied to Higher Risk for DementiaDrug Might Stop Heart Trouble Linked to Sickle Cell AnemiaChild Obesity Rose Sharply During PandemicFDA Advisory Panel to Meet on COVID Booster ShotsStatin Cholesterol Drugs May Help Fight Ulcerative ColitisAHA News: Physical Activity Is Helpful After a Stroke, But How Much Is Healthy?Special 'Strategies' Can Help People With Parkinson's Walk, But Many Patients UnawareEven When Undergoing Treatment, People With MS Gain From COVID VaccinesNIH Spending Nearly $470 Million on Long-Haul COVID StudyHospitalizing the Unvaccinated Has Cost U.S. Nearly $6 BillionIn 16 States, 35% or More Residents Now Obese: CDCPet Store Puppies Passing Drug-Resistant Bacteria to PeopleIs a Combo COVID/Flu Shot on the Way?1 in 500 Americans Has Died From COVID-19Having Even a Cousin or Grandparent With Colon Cancer Raises Your Risk: StudyBlood Cancer Patients Could Benefit From COVID Booster Shot: StudyWHO Says Africa Will Get 30% of COVID Vaccines It Needs by FebruaryCOVID Vaccines for Kids Under 12 Could Come This Fall: FauciEbola Vaccine Effective in African Clinical TrialBritain OK's COVID Vaccine for Kids 12 and Older; Hopes to Avoid LockdownsIsraeli Data on COVID Boosters to Be Published This Week in Major Journal
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Few Symptoms After Your COVID Shot? Don't Worry, You Still Got Immune Boost

HealthDay News
by Robert Preidt
Updated: Sep 3rd 2021

new article illustration

FRIDAY, Sept. 3, 2021 (HealthDay News) -- Just because you didn't have a significant reaction after your COVID-19 shot doesn't mean it's not working, researchers say.

"It wasn't known if a lack of symptoms following vaccination or prior SARS-CoV-2 infection would indicate a less-than-adequate antibody response in people who received either the Pfizer/BioNTech or Moderna vaccines, so we studied an available group of staff from our hospital to see if there were any connections," senior author Dr. Aaron Milstone said in a Johns Hopkins news release. He's an associate hospital epidemiologist at Johns Hopkins Hospital in Baltimore.

The study included more than 950 health care workers who had received both doses of either the Pfizer/BioNTech or Moderna vaccines. Some also had a confirmed prior SARS-CoV-2 infection.

Participants self-reported symptoms after vaccination as none; mild (injection site pain, mild fatigue or headache), or clinically significant (fatigue, fever or chills).

Five percent reported clinically significant symptoms after their first shot, as did 43% after the second dose.

After adjusting for age, sex and prior COVID infection, researchers found that people who got the Moderna vaccine were more likely to have significant symptoms after either dose.

Prior COVID infection was linked with an increased chance of clinically significant symptoms after one dose but not two.

Regardless of symptoms, 99.9% of participants developed antibodies against the coronavirus 14 or more days after their second vaccine dose, according to findings recently published in the journal JAMA Internal Medicine.

The only participant who didn't develop antibodies was taking an immunosuppressant medication.

Factors associated with higher antibody levels were clinically significant symptoms; being younger than 60; being female; getting the Moderna vaccine; and prior SARS-CoV-2 exposure.

"The findings suggest that either spike mRNA vaccine will work well against SARS-CoV-2, even if a person doesn't experience symptoms after vaccination or if they had a prior infection by the virus," said lead author Amanda Debes, assistant scientist in international health at Hopkins' Bloomberg School of Public Health. "This should help reduce anxieties that the vaccines will be less effective in either situation."

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19 vaccines.

SOURCE: Johns Hopkins Medicine, news release, Aug. 25, 2021